GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today ...
Investor's Business Daily on MSN10m
Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.